Tectonic announced favorable early safety and drug-handling results for TX2100. This supports its treatment effort, though the filing gives no study figures or proof the treatment works.
Encouraging early safety and drug-handling findings can help TX2100's testing progress. The filing gives no study figures, so this is an early sign, not proof the treatment works.
Follow Tectonic Therapeutic, Inc. (TECX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TECX